Table 2.
Association of MetS and each of its components with onset of depressive symptoms over the 4-year follow-up by age-quartile group
| Age-groups | Without MetS or components [n (% depressed)] | With MetS or components, [n (% depressed)] | Odds ratio (95% CI)* | P |
|---|---|---|---|---|
| Overall MetS | ||||
| 65.0–69.4 | 989 (14.8) | 123 (21.1) | 1.73 (1.02–2.95) | 0.04 |
| 69.4–72.8 | 963 (16.4) | 148 (16.9) | 1.18 (0.70– 1.97) | 0.58 |
| 72.8–76.8 | 960 (19.8) | 152 (20.4) | 0.94 (0.57–1.52) | 0.81 |
| 76.8–91.1 | 960 (22.9) | 151 (20.5) | 0.89 (0.56–1.42) | 0.63 |
| Central obesity component† | ||||
| 65.0–69.4 | 863 (14.6) | 249 (18.5) | 1.18 (0.80–1.75)† | 0.40 |
| 69.4–72.8 | 821 (16.0) | 290 (17.9) | 1.00 (0.68–1.46)† | 0.99 |
| 72.8–76.8 | 801 (19.5) | 311 (20.9) | 0.98 (0.69–1.38)† | 0.91 |
| 76.8–91.1 | 770 (22.5) | 341 (22.9) | 0.86 (0.62–1.19)† | 0.37 |
| High triglyceride component | ||||
| 65.0–69.4 | 933 (15.4) | 179 (15.6) | 1.14 (0.71–1.84) | 0.58 |
| 69.4–72.8 | 916 (16.5) | 195 (16.4) | 1.11 (0.71–1.74) | 0.63 |
| 72.8–76.8 | 947 (19.4) | 165 (22.4) | 1.18 (0.77–1.80) | 0.45 |
| 76.8–91.1 | 943 (22.7) | 168 (22.0) | 0.99 (0.65–1.50) | 0.95 |
| Low HDL cholesterol component | ||||
| 65.0–69.4 | 1,025 (14.8) | 87 (23.0) | 1.81 (1.04–3.17) | 0.03 |
| 69.4–72.8 | 998 (16.5) | 113 (15.9) | 1.03 (0.59–1.80) | 0.91 |
| 72.8–76.8 | 1,009 (19.4) | 103 (24.3) | 1.23 (0.74–2.03) | 0.42 |
| 76.8–91.1 | 1,021 (22.1) | 90 (27.8) | 1.37 (0.82–2.29) | 0.22 |
| Hypertension component | ||||
| 65.0–69.4 | 274 (18.6) | 838 (14.4) | 0.88 (0.60–1.30) | 0.53 |
| 69.4–72.8 | 229 (21.8) | 882 (15.1) | 0.70 (0.47–1.03) | 0.07 |
| 72.8–76.8 | 193 (26.9) | 919 (18.4) | 0.63 (0.43–0.92) | 0.02 |
| 76.8–91.1 | 175 (25.7) | 936 (22.0) | 0.91 (0.61–1.33) | 0.62 |
| High fasting blood glucose component | ||||
| 65.0–69.4 | 991 (15.3) | 121 (16.5) | 1.25 (0.70– 2.21) | 0.45 |
| 69.4–72.8 | 982 (15.8) | 129 (21.7) | 1.80 (1.10– 2.96) | 0.02 |
| 72.8–76.8 | 973 (20.1) | 139 (18.0) | 0.88 (0.54– 1.45) | 0.63 |
*Odds ratio adjusted for age at baseline (by year), sex, study center, MetS treatment (use of lipid-lowering drugs or antihypertensive drugs), educational attainment, marital status, smoking, alcohol consumption, cognitive deficit (MMSE <24), disability (assessed by the IADL scale), BMI, and self-reported history of CVD (including stroke) at baseline. The reference (odds ratio = 1) corresponded to the subjects without MetS (or MetS components) for each age-group and conditions.
†BMI categories were not included in this model.